News
Regeneron, playing catch up with J&J and Pfizer, wins FDA approval for Lynozyfic in multiple myeloma
Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...
China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...
Just days after President Donald Trump was elected in November, AstraZeneca unvei | AstraZeneca CEO Pascal Soriot is plotting ...
Generic and biosimilar specialist Sandoz is strengthening its footprint in Slovenia, pledging $440 million to set up a new ...
After taking aim at the United States’ vaccine safety reporting system earlier this year, Robert F. Kennedy Jr. | After ...
Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...
As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...
As Dry Eye Awareness Month kicks off, Bausch + Lomb is rolling out a new campaign to improve education about the condition. | ...
Despite the popularity of generic and biosimilar drugs in Europe—the latter of which have struggled to catch on in the ...
Restricted availability under an FDA-mandated drug safety program has limited the reach of CAR-T cell therapies for certain ...
Thanks to his trusty Dexcom continuous glucose monitor (CGM), former boy band star Lance Bass is saying “bye bye bye” to ...
In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results